Bayer Common Stock Dividends Paid 2010-2025 | BAYRY

Bayer annual/quarterly common stock dividends paid history and growth rate from 2010 to 2025. Common stock dividends paid can be defined as the cash outflow for dividends paid on a company's common stock
  • Bayer common stock dividends paid for the quarter ending March 31, 2025 were $0M, a 0% increase year-over-year.
  • Bayer common stock dividends paid for the twelve months ending March 31, 2025 were $-0.393B, a 94.91% decline year-over-year.
  • Bayer annual common stock dividends paid for 2024 were $-0.142B, a 94.49% decline from 2023.
  • Bayer annual common stock dividends paid for 2023 were $-2.575B, a 23.11% increase from 2022.
  • Bayer annual common stock dividends paid for 2022 were $-2.091B, a 11.3% decline from 2021.
Bayer Annual Common Stock Dividends Paid
(Millions of US $)
2024 $-142
2023 $-2,575
2022 $-2,091
2021 $-2,358
2020 $-3,162
2019 $-2,929
2018 $-2,843
2017 $-2,672
2016 $-2,353
2015 $-2,075
2014 $-2,312
2013 $-2,091
2012 $-1,757
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $30.141B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $753.564B 57.78
Johnson & Johnson (JNJ) United States $365.747B 15.12
AbbVie (ABBV) United States $329.946B 18.19
Novo Nordisk (NVO) Denmark $302.281B 20.03
Roche Holding AG (RHHBY) Switzerland $262.643B 0.00
Novartis AG (NVS) Switzerland $254.167B 14.51
Merck (MRK) United States $197.945B 10.12
Pfizer (PFE) United States $137.813B 7.55
Sanofi (SNY) France $118.626B 11.68
Innoviva (INVA) United States $1.280B 13.41